3rd Quarter - Report — VERTEX PHARMACEUTICALS INCORPORATED for VERTEX PHARMACEUTICALS INCORPORATED (2025)

Firm

VERTEX PHARMACEUTICALS INCORPORATED

Client

VERTEX PHARMACEUTICALS INCORPORATED

Income

—

Expenses

$1,110,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Federal policies impacting pharmaceutical development, approval, and reimbursement; Copay accumulators and maximizers, S.864 - HELP Copays Act; Alternative Funding Programs; Unmet medical need in acute pain; Barriers to patient access of non-opioid pain medicines; General education about kidney disease, including APOL-1; Cystic Fibrosis; Sickle cell disease; Innovations in Type 1 diabetes treatments.

Lobbyist	Covered position, as disclosed
HANNAH BETH CORNWELL	—
KRISTIN RICHTER	—
MATTHEW O SCHUMAKER	—
SWARNA VALLURUPALLI	—

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 864 (119th)

Medicare/Medicaid MMM

Unmet medical need in acute pain; H.R. 1227/S. 475 - The Alternatives to PAIN Act; Implementation of Public Law No: 117-328 sec. 4135 NO PAIN Act; Medically necessary fertility treatments for patients undergoing fully myeloablative conditioning; CMMI demo focusing on sickle cell disease; Drug Pricing Policies including Most Favored Nation policy proposals.

Lobbyist	Covered position, as disclosed
HANNAH BETH CORNWELL	—
KRISTIN RICHTER	—
MATTHEW O SCHUMAKER	—
SWARNA VALLURUPALLI	—

Contacted: Centers For Medicare and Medicaid Services (CMS); Vice President of the U.S.; Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; Food & Drug Administration (FDA); White House Office; SENATE; Congressional Budget Office (CBO)

Bills named: H.R. 1227 (119th), S. 475 (119th)

Taxation/Internal Revenue Code TAX

Corporate tax reform; H.R. 1414 - Cameron's Law, Preservation of Orphan Drug Tax Credit; Restoration of Sec 174 R&D Expense Deductibility.

Lobbyist	Covered position, as disclosed
SWARNA VALLURUPALLI	—

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1414 (119th)

Budget/Appropriations BUD

Education about non-opioid pain therapies and patient access to non-opioid medicines; Education on alternative funding programs; Education on the Million Veteran Program at the VA.

Lobbyist	Covered position, as disclosed
HANNAH BETH CORNWELL	—
KRISTIN RICHTER	—
MATTHEW O SCHUMAKER	—
SWARNA VALLURUPALLI	—

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Trade (domestic/foreign) TRD

Intellectual property reforms to address unfair trade practices in Argentina and Russia.

Lobbyist	Covered position, as disclosed
MATTHEW O SCHUMAKER	—

Contacted: U.S. Trade Representative (USTR)

Pharmacy PHA

Issues related to the National Defense Authorization Act - access to non-opioids for service members and their families; Issues related to the NDAA S.Amdt.3841 BIOSECURE Act.

Lobbyist	Covered position, as disclosed
HANNAH BETH CORNWELL	—
KRISTIN RICHTER	—
SWARNA VALLURUPALLI	—

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.